期刊
MICROORGANISMS
卷 10, 期 7, 页码 -出版社
MDPI
DOI: 10.3390/microorganisms10071299
关键词
mycobacteria; Mycobacterium tuberculosis; drug resistance; nucleoside analogues; inhibitors; thymidine monophosphate kinase; thymidylate synthase
类别
资金
- Russian Foundation for Basic Research (RFBR) [20-04-00094]
- Russian Science Foundation [19-74-10048]
Tuberculosis is the oldest human infection disease, and a significant number of the world's population is currently infected with Mycobacterium tuberculosis. Despite a decrease in mortality, the emergence of multidrug-resistant strains has created an urgent need for new anti-TB drugs. Nucleoside analogues have shown antimycobacterial activity, but no clinically used drugs based on them exist yet.
Tuberculosis (TB) is the oldest human infection disease. Mortality from TB significantly decreased in the 20th century, because of vaccination and the widespread use of antibiotics. However, about a third of the world's population is currently infected with Mycobacterium tuberculosis (Mtb) and the death rate from TB is about 1.4-2 million people per year. In the second half of the 20th century, new extensively multidrug-resistant strains of Mtb were identified, which are steadily increasing among TB patients. Therefore, there is an urgent need to develop new anti-TB drugs, which remains one of the priorities of pharmacology and medicinal chemistry. The antimycobacterial activity of nucleoside derivatives and analogues was revealed not so long ago, and a lot of studies on their antibacterial properties have been published. Despite the fact that there are no clinically used drugs based on nucleoside analogues, some progress has been made in this area. This review summarizes current research in the field of the design and study of inhibitors of mycobacteria, primarily Mtb.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据